Anika Therapeutics, Inc. ANIK
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 120.65M | 116.26M | 112.82M | 112.81M | 123.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.65M | 116.26M | 112.82M | 112.81M | 123.74M |
| Cost of Revenue | 45.65M | 48.14M | 49.01M | 50.45M | 75.53M |
| Gross Profit | 75.00M | 68.12M | 63.81M | 62.36M | 48.22M |
| SG&A Expenses | 50.31M | 52.37M | 49.09M | 48.33M | 55.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.42M | 126.93M | 123.87M | 124.60M | 157.22M |
| Operating Income | -2.76M | -10.67M | -11.05M | -11.80M | -33.48M |
| Income Before Tax | -2.91M | -10.26M | -9.31M | -10.03M | -35.41M |
| Income Tax Expenses | 208.00K | 818.00K | 672.00K | 4.23M | 5.60M |
| Earnings from Continuing Operations | -3.12 | -11.08 | -9.98 | -14.27 | -41.01 |
| Earnings from Discontinued Operations | -663.00K | 14.00K | -901.00K | -18.77M | -19.62M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.78M | -11.06M | -10.88M | -33.04M | -60.63M |
| EBIT | -2.76M | -10.67M | -11.05M | -11.80M | -33.48M |
| EBITDA | 2.87M | -5.27M | -5.47M | -6.10M | -27.00M |
| EPS Basic | -0.27 | -0.79 | -0.76 | -2.28 | -4.14 |
| Normalized Basic EPS | -0.02 | -0.39 | -0.41 | -0.41 | -1.35 |
| EPS Diluted | -0.28 | -0.80 | -0.77 | -2.29 | -4.16 |
| Normalized Diluted EPS | -0.02 | -0.38 | -0.40 | -0.41 | -1.35 |
| Average Basic Shares Outstanding | 55.55M | 56.59M | 57.35M | 57.66M | 58.01M |
| Average Diluted Shares Outstanding | 56.34M | 57.14M | 57.90M | 57.86M | 58.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |